HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: dc07-1526v1 31/3/562    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Musso, G. Articles by Cassader, M. PubMed PubMed Citation Articles by Musso, G. Articles by Cassader, M. Social Bookmarking                What's this?

Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome?

A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects

¹ Gradenigo Hospital, Turin, Italy
² Department of Internal Medicine, University of Turin, Turin, Italy

Address correspondence and reprint requests to Giovanni Musso, Gradenigo Hospital, Corso R. Margherita 8, 10132 Turin, Italy. E-mail: giovanni_musso{at}yahoo.it

	ABSTRACT

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

 
OBJECTIVE—The ability of the Adult Treatment Panel III (ATP III) criteria of metabolic syndrome to identify insulin-resistant subjects at increased cardiovascular risk is suboptimal, especially in the absence of obesity and diabetes. Nonalcoholic fatty liver disease (NAFLD) is associated with insulin resistance and is emerging as an independent cardiovascular risk factor. We compared the strength of the associations of ATP III criteria and of NAFLD to insulin resistance, oxidative stress, and endothelial dysfunction in nonobese nondiabetic subjects.

RESEARCH DESIGN AND METHODS—Homeostasis model assessment of insulin resistance (HOMA-IR) >2, oxidative stress (nitrotyrosine), soluble adhesion molecules (intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin), and circulating adipokines (tumor necrosis factor-, leptin, adiponectin, and resistin) were cross-sectionally correlated to ATP III criteria and to NAFLD in 197 unselected nonobese nondiabetic subjects.

RESULTS—NAFLD more accurately predicted insulin resistance than ATP III criteria: sensitivity 73 vs. 38% (P = 0.0001); positive predictive value: 81 vs. 62% (P = 0.035); negative predictive value 87 vs. 74% (P = 0.012); positive likelihood ratio 4.39 vs. 1.64 (P = 0.0001); and negative likelihood ratio 0.14 vs. 0.35 (P = 0.0001). Adding NAFLD to ATP III criteria significantly improved their diagnostic accuracy for insulin resistance. Furthermore, NAFLD independently predicted HOMA-IR, nitrotyrosine, and soluble adhesion molecules on logistic regression analysis; the presence of NAFLD entailed more severe oxidative stress and endothelial dysfunction, independent of adiposity or any feature of the metabolic syndrome in insulin-resistant subjects.

CONCLUSIONS—NAFLD is more tightly associated with insulin resistance and with markers of oxidative stress and endothelial dysfunction than with ATP III criteria in nonobese nondiabetic subjects and may help identify individuals with increased cardiometabolic risk in this population.

Abbreviations: ALT, alanine aminotransferase • ATP III, Adult Treatment Panel III • HOMA-IR, homeostasis model assessment of insulin resistance • ICAM-1, intercellular adhesion molecule-1 • NAFLD, nonalcoholic fatty liver disease • OGTT, oral glucose tolerance test • TNF-, tumor necrosis factor- • VCAM-1, vascular cell adhesion molecule-1

	INTRODUCTION

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

 
Metabolic syndrome is a cluster of metabolic and cardiovascular risk factors that sharing the hallmark of insulin resistance; its prevalence according to Adult Treatment Panel III (ATP III) criteria is 20% among Western adults (1). Insulin resistance is an independent predictor of cardiovascular disease and type 2 diabetes and should be identified and treated early (2–5).

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries (1). NAFLD predicts incident diabetes independent of classic risk factors and C-reactive protein in large prospective cohort studies and may therefore be an early marker of mechanisms predisposing to future metabolic events (1,6). In a parallel way, NAFLD is emerging as a marker of early atherosclerosis: liver enzymes predicted incident cardiovascular disease independent of traditional risk factors, C-reactive protein and metabolic syndrome, and liver histology correlated with early carotid atherosclerosis in NAFLD, suggesting that the vessels and the liver share common inflammatory mediators (7–9).

Despite the number of studies connecting fatty liver to insulin resistance, it is still unclear whether a diagnosis of NAFLD can help identify apparently healthy individuals with an increased cardiometabolic risk more accurately than current diagnostic criteria. ATP III criteria for metabolic syndrome correlate fairly well with insulin resistance (sensitivity of 46% and specificity of 76% for insulin resistance, respectively) in the general population, and this association is weaker in the absence of obesity and diabetes (10–13).

By directly comparing subjects with NAFLD with insulin-resistant subjects without fatty liver, we tested the hypotheses that 1) NAFLD might be more tightly associated with insulin resistance than current ATP III criteria in nonobese nondiabetic subjects and 2) fatty liver per se conveys a higher cardiovascular risk in otherwise healthy insulin-resistant subjects, independent of insulin resistance, metabolic syndrome, and circulating adipokines.

	RESEARCH DESIGN AND METHODS—

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

 
A total of 197 Caucasians (87 women, age range 24–63 years, BMI range 19.9–29.9 kg/m²) were selected from a population-based cohort participating in previous institutional studies over the past 5 years (14). All were nondiabetic and nonobese, in good general health, and with normal findings on medical history, physical examination, blood count, and chemical screening battery. Insulin resistance was defined by a homeostasis model assessment of insulin resistance (HOMA-IR) index >2. The HOMA-IR index closely correlated with clamp measures in nondiabetic Northern Italian subjects (15) and with oral glucose tolerance test (OGTT)-derived indexes of insulin sensitivity in our subjects with NAFLD (G.M., unpublished data); furthermore, a cutoff value >2 predicted insulin resistance and increased cardiovascular risk in the general population independent of traditional risk factors (2–4,14,15).

NAFLD was diagnosed by persistently (>6 months) elevated aminotransferases (defined by alanine aminotransferase [ALT] 30 units/l in men and 20 units/l in women, based on recently proposed cutoff values, which increase the sensitivity for detection of NAFLD) (16,17) and ultrasonographic bright liver with no other liver disease; histological confirmation was available for 66% of the subjects. Exclusion criteria were a history of alcohol consumption >70 g/week (assessed by a detailed inquiry of patients and relatives and a validated questionnaire filled in daily for 1 week by the patients); diabetes (fasting plasma glucose 126 mg/dl or 200 mg/dl at +2 h with a standard oral glucose load on an OGTT); obesity (BMI 30 kg/m²); positive serum markers of viral disease; and exposure to occupational hepatotoxins or to drugs known to be steatogenic or to affect glucose metabolism.

Modified ATP III criteria for the diagnosis of metabolic syndrome were the following: hypertension (systolic/diastolic blood pressure 130/85 mmHg or receiving antihypertensive therapy); hypertriglyceridemia (fasting plasma triglycerides 150 mg/dl [1.7 mmol/l] or receiving lipid-lowering therapy; low plasma HDL cholesterol (<40 mg/dl [1.03 mmol/l] in men and <50 mg/dl [1.29 mmol/l]) in women]); impaired glucose regulation (impaired fasting glycemia, i.e., fasting plasma glucose 100 but <126 mg/dl [5.6–7.0 mmol/l] or impaired glucose tolerance, i.e., plasma glucose 140 mg/dl [7.8 mmol/l] at +2 h on an OGTT]; or abdominal obesity, modified according to ethnic-specific cutoff values to increase sensitivity for "metabolically obese" lean subjects (for Europeans, cutoff ranges were a waist circumference >94 cm [37 inches] in men and >80 cm [31 inches] in women) (12). A diagnosis of metabolic syndrome required fulfillment of at least three criteria.

Oxidative stress
Nitrosative stress is believed to be involved in diabetic endothelial dysfunction and cardiovascular complications (1) and in liver oxidative injury in NAFLD (18,19). Fasting plasma nitrotyrosine, as a marker of nitrosative stress, was determined by a commercial ELISA kit product by HyCult Biotechnology (Pantec, Turin, Italy).

Endothelial dysfunction
Soluble adhesion molecules E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1) have been associated with endothelial dysfunction and early cardiovascular disease (20,21). Serum E-selectin, VCAM-1, and ICAM-1 levels were measured by a solid-phase ELISA (R&D Systems, Minneapolis, MN). Minimal detectable doses and intra- and interassay coefficients of variation (CVs) were, respectively, <0.1 ng/ml, 4.7–5.0%, and 7.4–8.8%, 0.17–1.26 pg/ml, 2.3–3.6%, and 5.5–7.8%, and <0.1 ng/ml, 4.7–5.0%, and 7.4–8.8%.

Adipokines
Serum tumor necrosis factor- (TNF-), leptin, and adiponectin were measured by a sandwich ELISA (R&D Systems Europe, Abingdon, UK). For TNF- the kit has a sensitivity of 0.12 pg/ml in a 200-µl sample size and a range of 0.5 to 32 pg/ml. Intra- and interassay CVs were 5.9 and 12.6%, respectively. For adiponectin, the kit has a sensitivity of 0.25 pg/ml in a 50-µl sample size and a range of 3.9 to 250 ng/ml. The intra- and interassay CVs were 3.4 and 5.8%, respectively. Resistin was measured by a biotin-labeled antibody-based sandwich enzyme immunoassay (BioVendor Laboratory Medicine, Brno, Czech Republic).

Statistics
Data are expressed as means ± SD. Differences between groups were analyzed by ANOVA when variables were normally distributed; otherwise (for triglycerides, insulin, HOMA-IR, adipokines, nitrotyrosine, and adhesion molecules), the Mann-Whitney test was used. A ² test was used to compare categorical variables. Normality was evaluated by the Shapiro-Wilk test. For multiple comparisons, ANOVA and the Kruskal-Wallis test, followed by the Bonferroni correction or a Dunn test, were used, as appropriate. Spearman correlation coefficients were used to estimate the relationship between variables. Logistic regression analysis was applied when multiple associations were detected on univariate analysis. Differences were considered statistically significant if P < 0.05.

Sensitivity, specificity, positive and negative predictive value, and likelihood ratios of different criteria for the presence of insulin resistance were calculated. The positive likelihood ratio is the true-positive rate divided by the false-positive rate; the negative likelihood ratio is the inverse of the true-negative rate divided by the false-negative rate. For each parameter 95% CIs were provided.

	RESULTS—

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

 
Of the subjects, 50% were overweight (39% of insulin-sensitive and 71% of insulin-resistant subjects) (Table 1). The prevalence of NAFLD was 30% (8% in insulin-sensitive and 73% in insulin-resistant subjects). Insulin-resistant subjects also had higher circulating markers of oxidative stress and endothelial dysfunction and lower adiponectin levels.

Relationship of ATP III criteria and NAFLD to insulin resistance
Table 2 shows the relationship of different ATP III criteria and of NAFLD to insulin resistance. Hypertension and NAFLD were the most sensitive (73% for both) and had the highest negative predictive value (81 and 87%, respectively) for insulin resistance. The negative likelihood ratio (i.e., the extent to which the odds of insulin resistance decrease if the test result is negative) was greatest with hypertension (0.23) and NAFLD (0.14). HDL cholesterol and NAFLD were most specific for insulin resistance (98 and 92%, respectively) and had the highest positive predictive value (83 and 81%, respectively) and positive likelihood ratio (i.e., the odds of insulin resistance if the test result is positive: 5.00 and 4.39, respectively).

Insulin resistance with NAFLD versus insulin resistance without fatty liver
With subgrouping of insulin-resistant subjects according to the presence of NAFLD, patients with NAFLD had higher levels of nitrotyrosine and of soluble adhesion molecules than subjects without fatty liver (Table 3).

On logistic regression analysis, HOMA-IR >2 was independently predicted by NAFLD, adiponectin, and nitrotyrosine (Table 4). Nitrotyrosine was independently predicted by NAFLD and C-reactive protein, NAFLD (β = 0.36; P = 0.008) and HOMA-IR independently predicted E-selectin, ICAM-1 was independently predicted by ALT and adiponectin, and adiponectin predicted VCAM-1 (Table 4).

	CONCLUSIONS—

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

The aim of the ATP III criteria is to identify individuals at increased risk for cardiovascular disease and diabetes to allow early treatment. Current ATP III criteria were selected because they tend to cluster together, share insulin resistance as their common denominator, and have individually been associated with an increased cardiovascular risk. However, they correlate weakly with the presence of insulin resistance, having a sensitivity and positive predictive value of 46 and 76%, respectively, in the general population (10). Because of their low sensitivity, many cases of insulin resistance remain undiagnosed, particularly in nonobese nondiabetic subjects, in whom the diagnosis of metabolic syndrome is less assisted by obesity and glucose criteria (10–13).

ATP III criteria consistently identified only 39% of insulin-resistant subjects in our population, with a positive predictive value of 62% and a positive likelihood ratio of 1.64. The presence of NAFLD alone doubled the sensitivity and significantly elevated positive predictive value and positive likelihood ratio, keeping the same specificity for insulin resistance (92% vs. 89%). The addition of NAFLD to the ATP III criteria improved their sensitivity by 72%, from 39 to 69%, with only a slight decrease in specificity, from 89 to 87%. Pathogenetically, these findings suggest that in nonobese nondiabetic subjects hepatic fat accumulation is more tightly related to insulin resistance than visceral adiposity, as estimated by waist circumference or any other feature of the metabolic syndrome, as defined by ATP III criteria.

The mechanism(s) underlying the association between NAFLD and insulin resistance are under investigation, but impaired hepatic lipid and lipoprotein handling and increased oxidative stress may enhance liver fat accumulation and lead to insulin resistance by nuclear factor-B pathway activation (22–26). Increased nitrosative stress, in particular, seems to be operating in NAFLD even in the absence of insulin resistance (27).

The second intriguing finding relates to the additive information that NAFLD carries in the setting of insulin resistance. Patients with NAFLD displayed more severe oxidative stress and endothelial dysfunction than nonsteatotic insulin-resistant subjects, despite similar HOMA-IR and adiposity, and NAFLD independently entailed more severe oxidative stress and endothelial dysfunction.

Nitrotyrosine is an index of peroxynitrite formation, which is believed to play a key role in diabetic endothelial dysfunction and in liver oxidative injury in NAFLD (18,19). Mechanisms underlying increased oxidative stress in NAFLD cannot be elucidated in our study, but impaired mitochondrial β-oxidation, dietary saturated fat excess, and reduced antioxidant intake have been proposed (22,23,26). Increased oxidative stress can induce not only steatosis but also necroinflammation and fibrosis in NAFLD: high oxidative stress experimentally impaired VLDL secretion, leading to hepatocyte triglyceride accumulation (24,28); oxidation end products trigger the inflammatory cascade and extracellular matrix deposition, paralleling the severity of liver fibrosis in NAFLD (23).

Soluble adhesion molecule levels were higher in NAFLD than in insulin resistance without fatty liver, and fatty liver predicted increased E-selectin and ICAM-1 levels independently of HOMA-IR, adipokines, and visceral fat accumulation. Plasma concentrations of these molecules were consistently related to incident cardiovascular disease in apparently healthy individuals in large prospective studies (20,21). Our findings therefore suggest that NAFLD may be an early marker of endothelial dysfunction, independently of insulin resistance and traditional risk factors (7). Mechanism(s) linking NALFD to endothelial dysfunction are unclear, but impaired lipoprotein metabolism and oxidized LDL accumulation are potential candidates (22,23,26,27).

In nonobese, nondiabetic insulin-resistant subjects, the presence of NAFLD may therefore indicate a host of unsuspected derangements in oxidative balance and endothelial function, not routinely assessed, that contribute to increased cardiovascular disease risk: in day-to-day clinical practice, a diagnosis of NAFLD would simply require chronically elevated liver enzyme levels, an ultrasonographic bright liver, and exclusion of viral infection and of exposure to hepatotoxins (including alcohol) by interview of patient and relatives. Early identification of such patients at higher cardiometabolic risk may trigger earlier lifestyle and pharmacological interventions. Consistently, therapeutic measures in NAFLD also ameliorate insulin sensitivity and cardiovascular risk profile, the ultimate goal of a diagnosis of metabolic syndrome (29–31).

Further studies are required to test the validity of this proposal and to overcome the limitations of our study: its cross-sectional nature, which prevents any causal inference, and the absence of obese and diabetic subjects. However, the prevalence of NAFLD and insulin resistance is even higher in obesity and diabetes, so the association between NAFLD and insulin resistance could be further strengthened. Consistent with previous findings, lower sex-specific ALT cutoff levels identified insulin-resistant subjects more accurately (16,17). However, because liver fat content was not directly measured, some control subjects might have fatty liver despite normal ultrasound and liver enzyme levels; even so, this definition of NAFLD proved to be useful in clinical practice. Furthermore, misclassification of NAFLD would attenuate the magnitude of the difference in oxidative stress and endothelial dysfunction observed toward the null hypothesis, making our results a conservative estimate of the relationship between NAFLD, oxidative stress, and endothelial dysfunction.

	Footnotes

 
Published ahead of print at http://care.diabetesjournals.org on 4 December 2007. DOI: 10.2337/dc07-1526.

Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/dc07-1526.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

Received for publication August 3, 2007. Accepted for publication November 19, 2007.

	References

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS-- RESULTS-- CONCLUSIONS-- References

 

1. Bloomgarden ZT: Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 28:1518–1523, 2005[Free Full Text]
   
2. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H: The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90:698–703, 2005
   
3. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV: Strong Heart Study: insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861–867, 2003[Abstract/Free Full Text]
   
4. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M: Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care 30:318–324, 2007[Abstract/Free Full Text]
   
5. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, Tahara H, Shoji T, Okuno Y, Nishizawa Y: Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care 26:2426–2432, 2003[Abstract/Free Full Text]
   
6. Sattar N, Scherbakova O, Ford I, O'Reilly DSJ, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 53:2855–2860, 2004[Medline]
   
7. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, Diamant M: Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191:391–396, 2007[Medline]
   
8. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541–3546, 2005[Medline]
   
9. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G: Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29:1325–1330, 2006[Abstract/Free Full Text]
   
10. St-Onge MP, Janssen L, Heymsfield SB: Metabolic syndrome in normal-weight Americans. Diabetes Care 27:2222–2228, 2004[Abstract/Free Full Text]
    
11. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES: Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53:1195–1200, 2004[Medline]
    
12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association, National Heart, Lung, and Blood Institute: Diagnosis and management of. the metabolic syndrome: an AHA/NHLBI Scientific Statement. Circulation 112:2735–2752, 2005[Free Full Text]
    
13. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:1066–1076, 2004[Abstract/Free Full Text]
    
14. Bo S, Gambino R, Uberti B, Mangiameli MP, Colosso G, Repetti E, Gentile L, Cassader M, Pagano GF: Does C-reactive protein identify a subclinical metabolic disease in healthy subjects? Eur J Clin Invest 35:265–270, 2005[Medline]
    
15. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57–63, 2000[Abstract]
    
16. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G: Updated definitions ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1–9, 2002[Abstract/Free Full Text]
    
17. Chang Y, Ryu S, Sung E, Jang Y: Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem 53:686–692, 2007[Abstract/Free Full Text]
    
18. Pacher P, Szabo C: Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 6:136–141, 2006[Medline]
    
19. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183–1192, 2001[Medline]
    
20. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation 96:4219–4225, 1997[Abstract/Free Full Text]
    
21. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351:88–92, 1998[Medline]
    
22. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Faga E, Pacini G, De Michieli F, Rabbione L, Premoli A, Cassader M, Pagano G: Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42:1175–1183, 2005[Medline]
    
23. Musso G, Cassader M, Gambino R, Durazzo M, Pagano G: Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH. Hepatology 43:1169–1170, 2006[Medline]
    
24. Pan M, Cederbaum AI, Zhang YL, Ginsberg HW, Williams KJ, Fisher FA: Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 113:1277–1287, 2004[Medline]
    
25. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G: Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology 45:1097–1107, 2007[Medline]
    
26. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Fagà E, Silli B, Pagano G: Dietary habits and their relations to insulin resistance and postprandial lipemia in non-alcoholic steatohepatitis. Hepatology 37:909–916, 2003[Medline]
    
27. Musso G, Gambino R, De Michieli F, Biroli G, Premoli A, Pagano G, Bo S, Durazzo M, Cassader M: Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am J Clin Nutr 86:661–671, 2007[Abstract/Free Full Text]
    
28. Botham KM, Zheng X, Napoletano M, Avella M, Cavallai C, Rivabene R, Bravo E: The effects of dietary n-3 polyunsaturated fatty acids delivered in chylomicron remnants on the transcription of genes regulating synthesis and secretion of verylow-density lipoprotein by the liver: modulation by cellular oxidative state. Exp Biol Med (Maywood) 228:143–151, 2003[Abstract/Free Full Text]
    
29. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS: Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Curr Med Res Opin 22:873–883, 2006[Medline]
    
30. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105, 2006[Medline]
    
31. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS: One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 100:1072–1081, 2005[Medline]
    

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				G. Musso, R. Gambino, S. Bo, and M. Cassader Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome? A Cross-Sectional Comparison With Adult Treatment Panel III Criteria in Nonobese Nondiabetic Subjects: Response to Sookoian et al. Diabetes Care, May 1, 2008; 31(5): e43 - e43. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: dc07-1526v1 31/3/562    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Musso, G. Articles by Cassader, M. PubMed PubMed Citation Articles by Musso, G. Articles by Cassader, M. Social Bookmarking                What's this?